tected. Other physical findings were unremarkable. Her blood glucose level was measured as 32 mg/dl. The simultaneous blood insulin level was 6.7 IU (normal range 5-25 IU). Other routine hematological and biochemical blood tests were within normal range. Electrocardiography was also normal. A 30% dextrose infusion was started, and the patient thereafter became fully conscious without any neurologic deficit. Although she did not take any insulin during dextrose infusion, her consequent blood glucose levels were measured as 54 and 62 mg/dl in the 1st and following the 4th h. On the 3rd day of levofloxacin treatment, another hypoglycemic episode was observed. During treatment with levofloxacin, she did not change her usual daily diet regimen. Levofloxacin was stopped, and we continued treatment with piperacillin tazobactam. No further episodes of hypoglycemia were observed during follow-up period.
The symptomatic hypoglycemia in our patient developed 1 day after initiating treatment with levofloxacin. Since no other apparent cause for hypoglycemia was found, levofloxacin was the most likely etiology of this dangerous and potentially fatal glucose abnormality. Levofloxacin is an increasingly popular broad-spectrum antibiotic. In general, it has an excellent safety profile and is considered safe in patients with penicillin or cephalosporin allergy (3) . Published reports about adverse effects of flouroquinolones are available for ciprofloxacin, gatifloxacin, clinafloxacin, and only one case of levofloxacin (2, 4, 5) .
The previously published reports about fluoroquinolone-associated hypoglycemia consisted of elderly patients with a history of type 2 diabetes, renal dysfunction, and receiving oral sulfonylureas (2,4). Our patient also had only diabetes. Consistent with most published case reports, the hypoglycemia in our patient was documented within 24 h of levofloxacin administration, and intravenous dextrose was required for correction of hypoglycemia. Other factors such as poor oral intake or renal dysfunction that could have contributed to the profound and prolonged hypoglycemia were not present in our patient. The mechanisms by which fluoroquinolones cause hypoglycemia are not fully understood. In one study, increased rat pancreatic islet cell insulin release was claimed to be the mechanism. This process was inhibited by drugs that antagonized adenosine triphosphate-sensitive K ϩ channels, suggesting that this channel is involved (6) . Use of the Naranjo ADR Probability Scale (7) indicated a probable relationship between the adverse effect of hypoglycemia and levofloxacin therapy in this patient. This case showed that even one dose of levofloxacin might be associated with significant and even fatal complications in geriatric patients without any previous renal dysfunction or impaired oral intake. To our knowledge, this is the first case of hypoglycemia related to levofloxacin in an elderly diabetic patient not using any oral antidiabetic drugs or insulin. The purpose of this letter is to caution physicians dealing with geriatric patients against the inappropriate use of flouroqunolones in these patients, especially in those with diabetes, since they may have a greater tendency to hypoglycemia. It might be important to monitor blood glucose levels early in the course of therapy. 
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C
igarette smoking causes a decrease in the glomerular filtration rate in diabetic patients with normal renal function, independent of confounding factors including severe proteinuria (1) . It increases the risk of microalbuminuria and accelerates the progression from microalbuminuria to overt proteinuria as well as the progression of renal failure in patients with type 2 diabetes (2). It is widely accepted that the rate of functional decline correlates with the degree of renal tubulointerstitial fibrosis. Previous studies have shown that renal function in patients with type 2 diabetes correlates better with tubular changes than with glomerular pathology (3) . Further studies on tubulointerstitial injury in patients with diabetic nephropathy may provide additional insight into the pathogenesis of diabetic nephropathy and lead to the identification of therapeutic targets. Livertype fatty acid-binding protein (L-FABP) is expressed in the proximal tubules, where it plays a key role in fatty acid metabolism. We and other investigators reported that urinary L-FABP may be a useful clinical marker for type 2 diabetic nephropathy (4 -6). However, little is known about the effect of cigarette smoking on the urinary L-FABP level.
Fifty type 2 diabetic patients with microalbuminuria (28 men and 22 women, mean age 50.0 years), including 30 smokers (18 men and 12 women) and 20 nonsmokers (10 men and 10 women), were enrolled in the present study. No patient had a serum creatinine (Cr) level Ͼ1.2 mg/dl. Urinary L-FABP levels were measured by an enzyme-linked immunoassay kit as described previously (4 -6). The urinary L-FABP level was significantly higher in smokers (20.5 Ϯ 10.5 g/g Cr) than in nonsmokers (10.5 Ϯ 5.5 g/g Cr) (P Ͻ 0.05). The smokers were divided into two groups: those who stopped smoking (n ϭ 10, group A) and those who continued smoking (n ϭ 20, group B). The angiotensin receptor blocker, ACE inhibitor, statin, antidiabetic drugs, and antiplatelet drugs used in the two groups were similar. After 24 months, the urinary L-FABP level in group A decreased significantly from 21.5 Ϯ 10.0 to 13.5 Ϯ 8.0 g/g Cr (P Ͻ 0.05); however, that in group B increased significantly from 20.0 Ϯ 11.0 to 27.5 Ϯ 15.5 g/g Cr (P Ͻ 0.05). These data suggest that cigarette smoking may be associated with tubulointerstitial injury in patients with early diabetic nephropathy. 
